Fate Therapeutics (FATE) Non-Current Debt (2012 - 2019)

Fate Therapeutics (FATE) has 8 years of Non-Current Debt data on file, last reported at $9.5 million in Q2 2019.

• Quarterly Non-Current Debt fell 26.23% year-over-year to $9.5 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $9.5 million (down 26.23% YoY) and the FY2018 annual result came in at $12.4 million, down 15.95% from the prior year.
• Non-Current Debt retreated to $9.5 million in Q2 2019, from $11.0 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $16.4 million in Q1 2015 to a low of $2.5 million in Q4 2016.
• A 5-year average of $10.7 million and a median of $11.3 million in 2018 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2016 — Non-Current Debt tumbled 76.6% — and 2017, when it surged 492.08%.
• Tracing FATE's Non-Current Debt over 5 years: stood at $10.7 million in 2015, then plunged by 76.6% to $2.5 million in 2016, then surged by 492.08% to $14.8 million in 2017, then decreased by 15.95% to $12.4 million in 2018, then dropped by 23.92% to $9.5 million in 2019.
• The last three Non-Current Debt figures came in at $9.5 million (Q2 2019), $11.0 million (Q1 2019), and $12.4 million (Q4 2018), per Business Quant data.